How has Haemonetics's payments for repurchase of common stock changed year-over-year?

Haemonetics's payments for repurchase of common stock decreased by 33.3% year-over-year, from $150M to $100M.

Haemonetics HAE Payments for Repurchase of Common Stock

Payments for Repurchase of Common Stock at other companies

TFX

TeleflexTFX

$0-100%

RepligenRGEN

$0—

MedtronicMDT

——

GE HealthCare TechnologiesGEHC

——

Bio-Rad LaboratoriesBIO

——

SolventumSOLV

——

Other financials

Income statement

See full

Revenue$346.4M+4.8%

Gross profit$198.2M+2.7%

Operating income$67.4M+14.2%

Net income$44.7M+19.3%

EPS (diluted)$0.95+28.4%

Balance sheet

See full

Cash & equivalents$245.4M-20.0%

Total debt$1.3B-0.7%

Total equity$796.3M-3.0%

Total assets$2.4B-2.2%

Cash flow

See full

Operating cash flow$70.9M-39.1%

CapEx$17.7M+12.9%

Free cash flow$53.3M-47.2%

Valuation

See full

Market cap$3.31B-18.0%

Profitability

See full

Gross margin59%+4.0pp

Operating margin19%+5.9pp

Net margin13.3%+3.8pp

FCF margin19.5%+9.1pp

Returns & leverage

See full

Return on equity19.3%+5.2pp

Debt / equity1.6×0.0×

Current ratio3×+1.3×

Where this comes from

Reported directly by Haemonetics in its filing.

Tagged under the XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock.

The official record: Haemonetics’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →

Ask your AI about Haemonetics's payments for repurchase of common stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Haemonetics's payments for repurchase of common stock?: Haemonetics (HAE) reported payments for repurchase of common stock of $100M in Q1 2026.
How has Haemonetics's payments for repurchase of common stock changed year-over-year?: Haemonetics's payments for repurchase of common stock decreased by 33.3% year-over-year, from $150M to $100M.